Michlewska, Sylwia published the artcileRuthenium metallodendrimers with anticancer potential in an acute promyelocytic leukemia cell line (HL60), Quality Control of 219508-27-7, the publication is European Polymer Journal (2017), 39-47, database is CAplus.
Ruthenium belongs to the family of metals widely used in anticancer therapy (platinum, arsenic, antimony, bismuth, gold, vanadium, iron, rhodium, titanium, gallium). This paper deals with a new kind of ruthenium terminated carbosilane dendrimers (CRD), consisting of carbosilane dendrons functionalized with N-, NH2-donor monodentate and N,N-chelating ruthenium complexes. The biophys. characterization, hemolytic activity and the cytotoxicity towards cancer (HL-60) and normal (B-14) cell lines of CRDs have been determined The data indicate that: (1) generation 0 metallodendrimers are the most effective drugs, being non-toxic for normal cells but induced significant cytotoxicity (>90%) in cancer cells; (2) an increase of generation leads both increased cytotoxicity of CRDs and the leveling of the difference in their action on normal and cancer cells; (3) coordination modes of ruthenium in a dendrimer scaffold did not correlate with their cytotoxicity towards normal and cancer cells. Results suggest that ruthenium dendrimers can be considered as alternative anticancer therapeutic agent.
European Polymer Journal published new progress about 219508-27-7. 219508-27-7 belongs to triazoles, auxiliary class Trifluoromethylated Building Blocks, name is 2-[5-(Trifluoromethyl)-1H-1,2,4-triazol-3-yl]pyridine, and the molecular formula is C8H5F3N4, Quality Control of 219508-27-7.
Referemce:
https://en.wikipedia.org/wiki/1,2,3-Triazole,
Triazoles – an overview | ScienceDirect Topics